Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Serina Therapeutics Inc. operates within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action in its patent portfolio. This action is assigned to 1 distinct examiner and is located within a distinct art unit. The portfolio's focus on Biotechnology & Pharmaceuticals involves a single point of contact at the patent office for its current pending matter.
KIM, DANIELLE A is identified as the busiest examiner for the portfolio. This examiner is responsible for the busiest examiner pending office action. This figure accounts for the total pending office actions for the company. The examiner KIM, DANIELLE A is the only individual currently reviewing pending office actions for the company.
The alignment of prosecution across the distinct examiner and the distinct art unit shows the distribution of the workload. KIM, DANIELLE A is the sole examiner handling the busiest examiner pending office action. This arrangement in the Biotechnology & Pharmaceuticals area means the company's current patent office interactions are limited to this single examiner and art unit. Practitioners should note that all current prosecution activity is consolidated under these specific parameters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18391869 | TARGETING OF ANTIGEN-PRESENTING CELLS BY NANOPARTICLES CONTAINING POLYOXAZOLINE-LIPID CONJUGATES | KIM, DANIELLE A | 63d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18391869 | TARGETING OF ANTIGEN-PRESENTING CELLS BY NANOPARTICLES CONTAINING POLYOXAZOLINE-LIPID CONJUGATES | KIM, DANIELLE A | 1613 | §103 | Final Rejection | 63d | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial